Search research articles
Contact Us
Filters
Showing results (21-30 of 166) with videos related to
Page
of 17
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development
N R Cutler, J J Sramek
Alzheimer Disease and Associated Disorders
|
January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"
N R Cutler, J J Sramek
Experimental Aging Research
|
January 1, 1983
Assessing the noradrenergic system in normal aging: a review of methodology
N R Cutler, J E Hodes
Comprehensive Psychiatry
|
January 1, 1979
The effect of one night's sleep loss on mood and memory in normal subjects
N R Cutler, H B Cohen
The American Journal of Psychiatry
|
November 1, 1977
Proven asymptomatic eosinophilia with imipramine
N R Cutler, D J Anderson
Journal of Clinical Pharmacology
|
November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?
N R Cutler, J J Sramek
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|
December 9, 2000
Women's health care during the perimenopause
E J Frackiewicz, N R Cutler
Alzheimer Disease and Associated Disorders
|
July 3, 1998
Guidelines for conducting bridging studies in Alzheimer disease
N R Cutler, J J Sramek
The American Journal of Psychiatry
|
January 1, 1978
Who was first?
N R Cutler, D J Anderson
European Journal of Clinical Pharmacology
|
January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study
N R Cutler, J J Sramek
Page
of 17
Search research articles
Search
Showing results (21-30 of 166) with videos related to
Sort By:
Page
of 17
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development
N R Cutler, J J Sramek
Alzheimer Disease and Associated Disorders
|
January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"
N R Cutler, J J Sramek
Experimental Aging Research
|
January 1, 1983
Assessing the noradrenergic system in normal aging: a review of methodology
N R Cutler, J E Hodes
Comprehensive Psychiatry
|
January 1, 1979
The effect of one night's sleep loss on mood and memory in normal subjects
N R Cutler, H B Cohen
The American Journal of Psychiatry
|
November 1, 1977
Proven asymptomatic eosinophilia with imipramine
N R Cutler, D J Anderson
Journal of Clinical Pharmacology
|
November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?
N R Cutler, J J Sramek
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|
December 9, 2000
Women's health care during the perimenopause
E J Frackiewicz, N R Cutler
Alzheimer Disease and Associated Disorders
|
July 3, 1998
Guidelines for conducting bridging studies in Alzheimer disease
N R Cutler, J J Sramek
The American Journal of Psychiatry
|
January 1, 1978
Who was first?
N R Cutler, D J Anderson
European Journal of Clinical Pharmacology
|
January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study
N R Cutler, J J Sramek
Page
of 17